Drug intelligence / Profile preview

ABSK201

Development stage: Phase 2
Lead developer: Absci
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous Injection

Overview

ABSK201 is a monoclonal antibody under development by AbSci. It targets the prolactin receptor (PRLR) and is being investigated for the treatment of androgenic alopecia (hair loss) and endometriosis. The drug is designed to activate dormant hair follicles, promoting their transition from the telogen to the anagen phase, and has shown robust hair regrowth in preclinical models. It is administered via long-lasting subcutaneous injection.

Other names: ABS201ABS-201ABS 201ABSK201ABSK-201ABSK 201

Targets

PRLR (Prolactin receptor)

Beyond the preview

Go deeper on ABSK201.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABSK201.

Explore the full profile